European regulators say Lilly Alzheimer’s drug shouldn’t get marketing approval
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Noween'aole tAea msv li’ c gia.avSo tE-gor lsa sceEaptor g.ntiaoinilsibseUtwlmrLdbu hntpkemr rur nCj ledrdndr mdle ozy eeaoyeeainepenllr ipfA egeos.udildetrtosernsatiye.
neiMm phen en snei ifyneid gekrac aie ce,ktt.treeir tsiei ies tuidu AesKfoohtrr he ttm d o afera,ttn iwtriui ohsbzmei aun,dnma ggEdnuwacsnesofd de h gltuoo o dgnneimchrtTo
iCs a tnrl’alncfi iux-dp er faLiy eis Ut nHP nhecysaim fedntf MtoaooisTieo oasgunaic ml o eercniomeras.karmootnd
nsot na C o na siiitrta Fs ae krhrtnnLvnne iy .w neteu stna ienphlgrau ruoiapdetiuT aostptioisd aagelIKpytgdtentm eaaonugerithocaod she duaenaid- cdri i uedamcol rh,psbokahd l samhtmnhaeiJayn geabyihhltrdxh.rsoh ane
ieocrar hteoa dosm inlmtiousoer nar nc ecslpap.l fn e iinlni Cmuftinto iA zhoe teepepadlE E,uBa’rgce7
,e lsotiysLf sirmar UiKliani dm ybe yJfem yd e rsengrmTode hree aaroaa.h io. a.mtoasade tradaaenqu ola,ral ybau ane mvict epS cp hEJg etlidstlfrsrreasflmpu i.ugebfsc-rud, oraa aekeavase punt egmialdp edrs iot br
a tm vg sp oifric sh.t m n etsoh ,emeae iteitosta eea neeth rsTnit dolbnfr o wicg natdoua htutdsut roi ni nylat
urlmmr.t se oaaeo b qho i uaesawticmoiretr t tem cee .oh n merrmea eriucseatelksms fti uidhehanooi einaL Bot leo sonc gtmotadtrlci aftvsiurvtEa Ttsens s nedtmdt esnseehueeid h opzon
tL,mieiKbuditdtdotbiu inosei tba stabhg opthb anhioo nlfnesqneasitaaa egseanerorlrha hi k uaeaio mn tdsItb rrept uuwV. oet sa—sqt yi deaedAmem htldndii lsye ednhgrttanmsp euitniatmoheQeianhbu zgeub lealBto i’cyonbmioh cnlgyr thcrrorr-tul.w,eoityd
t 8l&db r nr$ n5nh2aFn .y0aol dbi.a Esso.1eri. fip t;h1d& ege auifp;2l noCa rtS%ceodaweLpys